A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

September 9, 2015

Primary Completion Date

April 20, 2017

Study Completion Date

April 20, 2017

Conditions
Osteoarthritis
Interventions
DRUG

SM04690

DRUG

Placebo

Trial Locations (36)

14127

Research Site, Orchard Park

14609

Research Site, Rochester

16635

Research Site, Duncansville

21702

Research Site, Frederick

22911

Research Site, Charlottesville

23225

Research Site, Richmond

27612

Research Site, Raleigh

28144

Research Site, Salisbury

29464

Research Site, Mt. Pleasant

30189

Research Site, Woodstock

32216

Research Site, Jacksonville

33134

Research Site, Coral Gables

33173

Research Site, Miami

33409

Research Site, West Palm Beach

33761

Research Site, Clearwater

36608

Research Site, Mobile

37912

Research Site, Knoxville

40504

Research Site, Lexington

45246

Research Site, Cincinnati

53132

Research Site, Franklin

57702

Research Site, Rapid City

63141

Research Site 1, St Louis

Research Site 2, St Louis

67114

Research Site, Newton

67205

Research Site, Wichita

77074

Research Site, Houston

78745

Research Site, Austin

80230

Research Site, Denver

84041

Research Site, West Layton

85029

Research Site, Phoenix

85712

Research Site, Tucson

91978

Research Site, Spring Valley

92020

Research Site, El Cajon

92270

Research Site, Rancho Mirage

02111

Research Site, Boston

01605

Research Site, Worcester

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY